Nableran (Meropenem)

Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins. This blocks the final step of peptidoglycan cross‑linking, weakening the wall and causing bacterial lysis. Its structure resists most β‑lactamases, giving it activity against many resistant Gram‑negative and Gram‑positive organisms.

The dosage of Nableran is determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and local guidelines. Dosing regimens are individualized and should follow the prescriber’s order and the product’s labeling.

Safety data for meropenem in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians must evaluate each case and discuss potential risks with the patient.

To request Nableran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Meropenem, the active ingredient in Nableran, offers a broad spectrum similar to imipenem‑cilastatin and ertapenem but has a slightly higher stability against certain β‑lactamases and better penetration into the central nervous system. Choice among carbapenems depends on infection site, pathogen susceptibility, patient renal function and local antimicrobial stewardship policies.

Nableran should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect from light, and avoid freezing or shaking. Do not use the product if it has been exposed to temperatures outside the recommended range.

Nableran is supplied as an injectable solution for intravenous infusion. It is administered by a healthcare professional using aseptic technique, typically over a set infusion time according to the prescriber’s order. Infusion rates may be adjusted based on patient tolerance and renal function.

Serious adverse events include severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, seizures (particularly in patients with renal impairment), and hematologic abnormalities like thrombocytopenia or neutropenia. Prompt recognition and medical intervention are essential if these events occur.

Nableran is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Caution is also advised for patients with a history of seizures, severe renal impairment, or those receiving interacting medications listed under major interactions.